SMTI - Sanara MedTech expects 119% growth in Q4 topline

• Medical technology company, Sanara MedTech ( NASDAQ: SMTI ) gives prelim Q4 numbers , expects topline revenue to be ~$15.3M, up 119% from last year. FY revenue is expected to be $45.8M, up 90% from previous year.
• Operating loss is expected to be between $2M-3.5M; FY operating loss is expected to be $11M-12.5M.
• Cash and cash equivalents were ~$9M as of December 31, 2022.
• Zach Fleming, CEO comments, “In 2022, Sanara saw significant net revenue growth as a result of increased sales of our surgical products including those we market through our acquisition of Scendia and the products we license from Cook Biotech Inc. The efficacy of our CellerateRX ^® Surgical line of products and our ability to offer an expanded portfolio of products were both key drivers of our success in 2022 and we believe they will continue to help drive growth in 2023.”

For further details see: